Larimar Therapeutics, Inc.

As of June 30, 2026, Larimar Therapeutics, Inc. carries a market capitalization of 274.25M, placing it among publicly traded companies globally. Its enterprise value stands at 141.81M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Larimar Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Larimar Therapeutics, Inc. has 103.88M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Larimar Therapeutics, Inc. maintains a current ratio of 4.70, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Larimar Therapeutics, Inc. posted a negative return on equity (ROE) of -139.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -109.49, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 69.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Larimar Therapeutics, Inc.'s stock has declined approximately 39.64% over the past 52 weeks. The 50-day moving average sits at 2.98, while the 200-day moving average is 3.31.

Over the twelve months ended June 30, 2026, Larimar Therapeutics, Inc. generated - - in revenue and converted that into -151.08M in net income, yielding earnings per share of -1.69. EBITDA reached -156.40M, while operating income came in at -156.67M.

As of June 30, 2026, Larimar Therapeutics, Inc. holds 136.78M in cash and equivalents against 4.34M in total debt, resulting in a net debt position of -81.13M. Total book value stands at 111.50M, with working capital of 110.73M providing operational flexibility.

Larimar Therapeutics, Inc. produced -136.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -133,920.90 in capital expenditures, free cash flow totaled -136.61M - equivalent to -1.53 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -57.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -55.14, meaning Larimar Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Larimar Therapeutics, Inc.'s most recent stock split took place on May 29, 2020 with a 12:1 split ratio.

As of June 30, 2026, Larimar Therapeutics, Inc. has an Altman Z-Score of -1.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.